ArticleMayo Clinic proceedings. Innovations, quality & outcomes2022

Risk for Postmarket Black Box Warnings in FDA-Approved Monoclonal Antibodies.

John B Hagan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.